Educational research content only. Not medical advice, diagnosis, or treatment. Nothing on this site is intended to promote human use, self-administration, or the substitution of professional healthcare.

NovaGenesis Peptide Research
← Peptide Library
RECOVERY RESEARCHBPC

BPC-157

A pentadecapeptide derived from a gastric protein, widely studied for soft tissue stability and recovery process research.

Half-Life
Short–Moderate
Onset
Moderate
Symbol
BPC
Category
Recovery

⏱ Half-Life

Short–Moderate duration profile

BPC-157 demonstrates a short–moderate half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Moderate measurable response

Onset is observed as moderate — a property that influences how researchers structure comparative studies versus other compounds in the recovery research category.

🧠 Key Notes

What makes it distinct

  • 01Notably stable across pH ranges in research conditions
  • 02Frequently paired with TB-500 in literature
  • 03One of the most cited recovery research peptides

🧬 Mechanism of Action

How it works

BPC-157 (Body Protection Compound) is a stable 15-amino-acid sequence isolated from a protective protein in human gastric juice. It modulates the nitric oxide (NO) system, upregulates VEGFR2 (driving angiogenesis), and accelerates fibroblast and tendon-cell proliferation. Unique among peptides, it remains structurally stable in gastric acid, allowing oral as well as injectable research administration. It also supports gut-barrier integrity, protects endothelial function, and modulates dopamine and serotonin signalling — giving it a broader systemic profile than purely localised repair peptides.

✨ Documented Benefits

What the research shows it supports

B01Accelerates tendon, ligament, and muscle repair in extensive preclinical literature.
B02Restores gut-lining integrity and supports inflammatory bowel research models.
B03Protects against NSAID- and alcohol-induced gastric damage in animal studies.
B04Promotes angiogenesis, improving microcirculation around injured or ischaemic tissue.
B05Demonstrates neuroprotective effects in models of CNS injury and stress.
B06Stable in gastric acid — one of the few peptides studied via oral administration.

🔍 Research Insights

What the literature shows

INSIGHT 01

Unusual stability in gastric acid makes it one of the few peptides studied via oral administration in animal models.

INSIGHT 02

Modulates the nitric oxide system and VEGFR2 signalling, supporting angiogenic activity in repair research.

INSIGHT 03

Hundreds of preclinical publications — one of the most heavily-studied repair peptides in the literature.

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Tendon, ligament, and gut-lining repair models.

USE CASE 02

Vascular regeneration and microcirculation studies.

USE CASE 03

Oral vs injectable bioavailability comparisons.

🔬 Study Deep Dive

Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract

Sikiric P, et al. · Current Pharmaceutical Design · 2011

Design

Comprehensive review of preclinical in-vivo experiments across rodent models.

Population

Rat and mouse models of GI ulceration, inflammatory bowel disease, and vascular injury.

Intervention

Oral and intraperitoneal BPC-157 across dose ranges of 10 ng–10 μg/kg.

Primary Finding

Consistent acceleration of mucosal healing, angiogenesis, and nitric-oxide system stabilisation with no reported toxicity across models.

TAKEAWAY

Establishes the mechanistic foundation for BPC-157's angiogenic and cytoprotective effects that underpin most subsequent tissue-repair research.

Read the full study ↗

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

  1. [01]

    Sikiric, P. et al. (2018). Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines, 6(4), 96.

    Biomedicines ↗
  2. [02]

    Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.

    Journal of Applied Physiology ↗
  3. [03]

    Seiwerth, S. et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 24(18), 1972–1989.

    Current Pharmaceutical Design ↗
  4. [04]

    Sikiric, P. et al. (2013). Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design, 19(1), 76–83.

    Current Pharmaceutical Design ↗

⚠️ Not Medical Advice

Educational research summary only

This profile summarises published research on BPC-157. It is not medical advice, diagnosis, or treatment, and it is not intended to promote human use, self-administration, or the substitution of professional healthcare. Discuss any health decision with a licensed clinician.

Continue Exploring

Also explore: TB-500, GHK-Cu, MOTS-c

TB-500 →GHK-Cu →MOTS-c →Half-Life Guide →Recovery Research →